AI assistant
GlaxoSmithKline PLC — Director's Dealing 2023
Feb 22, 2023
5262_dirs_2023-02-22_a69c2be3-d273-4924-b516-bd6620856561.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information ![]()
RNS Number : 7518Q
GSK PLC
22 February 2023
GSK plc (the 'Company')
Transaction notification
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Ms D Conrad | |||
| b) | Position/status | Chief People Officer | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary Shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
|||
| b) | Nature of the transaction | Acquisition of Ordinary Shares following the exercise of options granted on 29 November 2019 at the option price of £14.15 per Ordinary Share under the Company's ShareSave Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £14.15 | 636 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2023-02-17 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHSEWFIEEDSEEE